Deborah Toppmeyer
Impact in
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
Papers in
-
- Breast Cancer Treatment Studies 32
- Oncology 28
- Cancer Treatment and Pharmacology 10
- Cancer Immunotherapy and Biomarkers 6
- Drug Transport and Resistance Mechanisms 3
- Cancer-related Molecular Pathways 3
- Co-authors
- Bruce George Haffty (20 shared papers)Thomas J. Kearney (4 shared papers)Qifeng Yang (2 shared papers)Joanne Barnes Weidhaas (1 shared paper)Lyndsay N. Harris (1 shared paper)Susan A. Higgins (1 shared paper)Michael Reiß (1 shared paper)Eric P. Winer (7 shared papers)
- Journals
- Journal of Clinical Oncology (7 papers)International Journal of Radiation Oncology*Biology*Physics (6 papers)Frontiers in Oncology (4 papers)Annals of Oncology (4 papers)New England Journal of Medicine (3 papers)
- Partner nations
- United StatesCanadaJapan
In The Last Decade
Deborah Toppmeyer
80 papers receiving 7.3k citations
Deborah Toppmeyer's Hit Papers
Peers
Comparison fields: 5 of 108
- Cancer Research 4k
- Oncology 1.6k
- Genetics 612
- Pulmonary and Respiratory Medicine 427
- Health Informatics 31
Countries citing papers authored by Deborah Toppmeyer
This map shows the geographic impact of Deborah Toppmeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Toppmeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Toppmeyer more than expected).
Fields of papers citing papers by Deborah Toppmeyer
This network shows the impact of papers produced by Deborah Toppmeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Toppmeyer. The network helps show where Deborah Toppmeyer may publish in the future.
Co-authors
The 25 scholars most cited alongside Deborah Toppmeyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 87 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer Hit paper breakdown → | 2018 | 1708 |
| 2 | Prospective Validation of a 21-Gene Expression Assay in Breast Cancer Hit paper breakdown → | 2015 | 1040 |
| 3 | Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer Hit paper breakdown → | 2006 | 928 |
| 4 | Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 540 |
| 5 | Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer Hit paper breakdown → | 2019 | 391 |
| 6 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 329 |
| 7 | 2006 | 255 | |
| 8 | 2015 | 178 | |
| 9 | 2017 | 167 | |
| 10 | 2019 | 122 | |
| 11 | 2021 | 119 | |
| 12 | 1994 | 112 | |
| 13 | 2020 | 104 | |
| 14 | 2020 | 92 | |
| 15 | 2017 | 87 | |
| 16 | A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. | 1995 | 80 |
| 17 | 2014 | 75 | |
| 18 | 2004 | 71 | |
| 19 | Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. | 2002 | 69 |
| 20 | 2019 | 58 |
About Deborah Toppmeyer
Deborah Toppmeyer is a scholar working on Cancer Research, Oncology, Genetics, Molecular Biology and Statistics and Probability, having authored 87 papers that have together received 7.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (32 papers), BRCA gene mutations in cancer (16 papers), Cancer Treatment and Pharmacology (10 papers), Cancer therapeutics and mechanisms (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Chemotherapy-induced cardiotoxicity and mitigation (3 papers), Drug Transport and Resistance Mechanisms (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Cancer Research (4k citations), Oncology (1.6k citations), Genetics (612 citations), Pulmonary and Respiratory Medicine (427 citations) and Health Informatics (31 citations). Deborah Toppmeyer has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Bruce George Haffty, Thomas J. Kearney, Qifeng Yang, Joanne Barnes Weidhaas, Lyndsay N. Harris, Susan A. Higgins, Michael Reiß, Eric P. Winer, Hope S. Rugo and Kim Marie Hirshfield. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Frontiers in Oncology, Annals of Oncology and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.